Cargando…
Signal changes in T2-weighted MRI of liver metastases under bevacizumab—A practical imaging biomarker?
OBJECTIVE: The purpose of this study was to investigate signal changes in T2-weighted magnetic resonance imaging of liver metastases under treatment with and without bevacizumab-containing chemotherapy and to compare these signal changes to tumor contrast enhancement. MATERIALS AND METHODS: Retrospe...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108712/ https://www.ncbi.nlm.nih.gov/pubmed/32231380 http://dx.doi.org/10.1371/journal.pone.0230553 |
_version_ | 1783512829820665856 |
---|---|
author | Thüring, Johannes Kuhl, Christiane Katharina Barabasch, Alexandra Hitpass, Lea Bode, Maike Bünting, Nina Bruners, Philipp Krämer, Nils Andreas |
author_facet | Thüring, Johannes Kuhl, Christiane Katharina Barabasch, Alexandra Hitpass, Lea Bode, Maike Bünting, Nina Bruners, Philipp Krämer, Nils Andreas |
author_sort | Thüring, Johannes |
collection | PubMed |
description | OBJECTIVE: The purpose of this study was to investigate signal changes in T2-weighted magnetic resonance imaging of liver metastases under treatment with and without bevacizumab-containing chemotherapy and to compare these signal changes to tumor contrast enhancement. MATERIALS AND METHODS: Retrospective analysis of 44 patients, aged 36–84 years, who underwent liver magnetic resonance imaging including T2-weighted and dynamic contrast enhancement sequences. Patients received bevacizumab-containing (n = 22) or conventional cytotoxic chemotherapy (n = 22). Magnetic resonance imaging was obtained at baseline and at three follow-ups (on average 3, 6 and 9 months after initial treatment). Three independent readers rated the T2 signal intensity and the relative contrast enhancement of the metastases on a 5-point scale. RESULTS: T2 signal intensity of metastases treated with bevacizumab showed a significant (p<0.001) decrease in T2 signal intensity after initial treatment and exhibit compared to conventionally treated metastases significantly (p<0.001 for each follow-up) hypointense (bevacizumab: 0.70 ± 0.83 before vs. -1.55 ± 0.61, -1.91 ± 0.62, and -1.97 ± 0.52; cytotoxic: 0.73 ± 0.79 before vs. -0.69 ± 0.81, -0.71 ± 0.68, and -0.75 ± 0.65 after 3, 6, and 9 months, respectively). T2 signal intensity was strongly correlated with tumor contrast enhancement (r = 0.71; p<0.001). Intra-observer agreement for T2-signal intensity was substantial (κ = 0.75). The agreement for tumoral contrast enhancement between the readers was considerably lower (κ = 0.39). CONCLUSION: Liver metastases exhibit considerably hypointense in T2-weighted imaging after treatment with bevacizumab, in contrast to conventionally treated liver metastases. Therefore, T2-weighted imaging seems to reflect the effect of bevacizumab. |
format | Online Article Text |
id | pubmed-7108712 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-71087122020-04-03 Signal changes in T2-weighted MRI of liver metastases under bevacizumab—A practical imaging biomarker? Thüring, Johannes Kuhl, Christiane Katharina Barabasch, Alexandra Hitpass, Lea Bode, Maike Bünting, Nina Bruners, Philipp Krämer, Nils Andreas PLoS One Research Article OBJECTIVE: The purpose of this study was to investigate signal changes in T2-weighted magnetic resonance imaging of liver metastases under treatment with and without bevacizumab-containing chemotherapy and to compare these signal changes to tumor contrast enhancement. MATERIALS AND METHODS: Retrospective analysis of 44 patients, aged 36–84 years, who underwent liver magnetic resonance imaging including T2-weighted and dynamic contrast enhancement sequences. Patients received bevacizumab-containing (n = 22) or conventional cytotoxic chemotherapy (n = 22). Magnetic resonance imaging was obtained at baseline and at three follow-ups (on average 3, 6 and 9 months after initial treatment). Three independent readers rated the T2 signal intensity and the relative contrast enhancement of the metastases on a 5-point scale. RESULTS: T2 signal intensity of metastases treated with bevacizumab showed a significant (p<0.001) decrease in T2 signal intensity after initial treatment and exhibit compared to conventionally treated metastases significantly (p<0.001 for each follow-up) hypointense (bevacizumab: 0.70 ± 0.83 before vs. -1.55 ± 0.61, -1.91 ± 0.62, and -1.97 ± 0.52; cytotoxic: 0.73 ± 0.79 before vs. -0.69 ± 0.81, -0.71 ± 0.68, and -0.75 ± 0.65 after 3, 6, and 9 months, respectively). T2 signal intensity was strongly correlated with tumor contrast enhancement (r = 0.71; p<0.001). Intra-observer agreement for T2-signal intensity was substantial (κ = 0.75). The agreement for tumoral contrast enhancement between the readers was considerably lower (κ = 0.39). CONCLUSION: Liver metastases exhibit considerably hypointense in T2-weighted imaging after treatment with bevacizumab, in contrast to conventionally treated liver metastases. Therefore, T2-weighted imaging seems to reflect the effect of bevacizumab. Public Library of Science 2020-03-31 /pmc/articles/PMC7108712/ /pubmed/32231380 http://dx.doi.org/10.1371/journal.pone.0230553 Text en © 2020 Thüring et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Thüring, Johannes Kuhl, Christiane Katharina Barabasch, Alexandra Hitpass, Lea Bode, Maike Bünting, Nina Bruners, Philipp Krämer, Nils Andreas Signal changes in T2-weighted MRI of liver metastases under bevacizumab—A practical imaging biomarker? |
title | Signal changes in T2-weighted MRI of liver metastases under bevacizumab—A practical imaging biomarker? |
title_full | Signal changes in T2-weighted MRI of liver metastases under bevacizumab—A practical imaging biomarker? |
title_fullStr | Signal changes in T2-weighted MRI of liver metastases under bevacizumab—A practical imaging biomarker? |
title_full_unstemmed | Signal changes in T2-weighted MRI of liver metastases under bevacizumab—A practical imaging biomarker? |
title_short | Signal changes in T2-weighted MRI of liver metastases under bevacizumab—A practical imaging biomarker? |
title_sort | signal changes in t2-weighted mri of liver metastases under bevacizumab—a practical imaging biomarker? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108712/ https://www.ncbi.nlm.nih.gov/pubmed/32231380 http://dx.doi.org/10.1371/journal.pone.0230553 |
work_keys_str_mv | AT thuringjohannes signalchangesint2weightedmrioflivermetastasesunderbevacizumabapracticalimagingbiomarker AT kuhlchristianekatharina signalchangesint2weightedmrioflivermetastasesunderbevacizumabapracticalimagingbiomarker AT barabaschalexandra signalchangesint2weightedmrioflivermetastasesunderbevacizumabapracticalimagingbiomarker AT hitpasslea signalchangesint2weightedmrioflivermetastasesunderbevacizumabapracticalimagingbiomarker AT bodemaike signalchangesint2weightedmrioflivermetastasesunderbevacizumabapracticalimagingbiomarker AT buntingnina signalchangesint2weightedmrioflivermetastasesunderbevacizumabapracticalimagingbiomarker AT brunersphilipp signalchangesint2weightedmrioflivermetastasesunderbevacizumabapracticalimagingbiomarker AT kramernilsandreas signalchangesint2weightedmrioflivermetastasesunderbevacizumabapracticalimagingbiomarker |